Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds

 
• By Alaric DeArment
Gilead's magrolimab is mostly back on track after the FDA lifted a partial hold on two key indications • Source: Alamy

More from Clinical Trials

More from R&D